Groundbreaking Developments in Health and Pharmaceutical Sector

This health news roundup highlights the FDA's initiatives to lower biologic drug costs, US-China tensions over fentanyl, a novel artificial cornea made from fish scales, and significant corporate moves in the pharmaceutical industry. Other topics include Medicaid coverage for gender-affirming surgery, measles cases in South Carolina, and advances in kidney transplant equality.

The U.S. Food and Drug Administration (FDA) has introduced new guidelines intended to streamline biosimilar drug testing, dramatically reducing the cost of vital biologic medications used in treating diseases such as cancer. Despite these drugs accounting for 5% of prescriptions, their cost represents 51% of total drug expenditure.

Meanwhile, tensions between the U.S. and China flared at a U.N. drugs meeting, with the U.S. accusing China of facilitating the sale of fentanyl precursor chemicals. China rebuffed these charges, marking ongoing discord between the two nations amid broader conversations about tariffs and drug trade.

Additionally, researchers in Spain have developed a cost-effective artificial cornea using fish scales, offering an innovative solution to eye diseases requiring donor transplants. This breakthrough could alleviate transplant shortages, demonstrating the potential of biotechnological advancements in addressing global medical challenges.

(With inputs from agencies.)